IgA nephropathy
Conditions
Interventions
treatment group:conventional treatment+ Yiqi Yangyin Qufeng formula
Sponsors
The Third Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Have been diagnosed with IgA nephropathy and meet the diagnostic criteria for CKD stage 1-2. (2) Have been diagnosed with the "Qi Yin Deficiency Syndrome" in TCM syndromes. (3) Adult subjects ages 18-75 years. (4) Have achieved good control of infections/electrolyte disorders/hypertension etc. (5) Have not participated in other clinical trials in the past six months and can comply with study procedures and follow-up.
Exclusion criteria
Exclusion criteria: (1) Patients who require immediate dialysis treatment and are currently receiving hormone nonsteroidal anti-inflammatory drug or immunosuppressive therapy; (2) Patients with severe arrhythmia acute heart failure myocardial infarction acute stroke unstable angina and NYHA grade IV; (3) Patients with acute infectious diseases and surgical and traumatic stress; (4) Merge patients with chronic infectious diseases such as active and delayed chronic hepatitis B decompensated liver cirrhosis or active tuberculosis; (5) Patients with severe organ dysfunction that affects survival such as malignant tumors HIV infection etc; (6) Patients with severe primary diseases such as cardiovascular hematological neurological digestive and respiratory systems and with a clear tendency towards bleeding; (7) Individuals with life-threatening complications such as hyperkalemia and heart failure; (8) The GFR fluctuation range within the first 3 months of enrollment is = 30%; (9) Individuals with severe allergic constitution who are allergic or intolerant to certain drugs known in this study; (10) Pregnant or lactating patients; (11) Individuals with a history of drug abuse or those who have been treated with immunosuppressants or glucocorticoids in the past 3 months; (12) Individuals with a history of major bleeding or blood transfusion in the past 3 months and signs of severe clinical infection or acidosis; (13) Patients who are currently participating in other clinical trials or who are using other traditional Chinese medicine treatments at the same time that affect the efficacy assessment; (14) Those who are preparing or have already undergone kidney transplantation and those with acute renal failure or chronic renal failure accompanied by acute exacerbation requiring immediate replacement therapy; (15) Patients with acute kidney damage caused by post-renal factors such as obstruction (including stones urate crystals tumors etc.); (16) Patients with a history of mental illness or communication cognitive impairment who have poor compliance and are unable to cooperate; (17)Non-yellow.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| URBC;24h UPQ; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome score scale;frequency of infections;UACR;eGFR; | — |
Countries
China
Contacts
Public ContactLu Keda
The Third Affiliated Hospital of Zhejiang Chinese Medical University
Outcome results
None listed